tiprankstipranks
Blueberries Medical Corp (TSE:BBM)
:BBM

Blueberries Medical (BBM) AI Stock Analysis

13 Followers

Top Page

TSE:BBM

Blueberries Medical

(BBM)

Select Model
Select Model
Select Model
Neutral 49 (OpenAI - 5.2)
Rating:49Neutral
Price Target:
C$0.02
▼(-25.00% Downside)
Action:UpgradedDate:01/28/26
The score is held back primarily by weak financial performance driven by ongoing losses and worsening cash burn, despite a cleaner low-debt balance sheet. Technicals provide some support with price above key moving averages and positive MACD, but overbought RSI/Stoch conditions temper the outlook. Valuation is constrained by negative earnings and no dividend support.
Positive Factors
Improved gross margin (~31% TTM)
A sustained gross margin near 31% indicates meaningful improvement in unit economics for cultivation and formulations. Over 2–6 months this supports variable-cost coverage, gives management margin leverage as revenue scales, and increases the realistic path to operating leverage if SG&A is controlled.
Negative Factors
Large operating losses / widening net loss
Persistent, large operating losses and a widening net loss are structural threats to equity value and reinvestment capacity. Over months this erodes retained capital, pressures management to cut investment or raise dilutive capital, and delays sustainable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved gross margin (~31% TTM)
A sustained gross margin near 31% indicates meaningful improvement in unit economics for cultivation and formulations. Over 2–6 months this supports variable-cost coverage, gives management margin leverage as revenue scales, and increases the realistic path to operating leverage if SG&A is controlled.
Read all positive factors

Blueberries Medical (BBM) vs. iShares MSCI Canada ETF (EWC)

Blueberries Medical Business Overview & Revenue Model

Company Description
Blueberries Medical Corp. engages in the growth, cultivation, development, production, and supply of medicinal cannabis and related products in Colombia. It offers medicinal-grade cannabis oil extracts and related products. The company is headquar...
How the Company Makes Money
Blueberries Medical generates revenue primarily through the sale of its medical cannabis products to licensed distributors, pharmacies, and healthcare providers. The company has established key revenue streams from its cultivation operations, wher...

Blueberries Medical Financial Statement Overview

Summary
Despite improved gross margin and very low debt, the company remains dominated by large operating losses and a widening net loss in TTM, with consistently negative operating cash flow and free cash flow that worsened versus 2024.
Income Statement
24
Negative
Balance Sheet
55
Neutral
Cash Flow
22
Negative
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue413.97K471.41K288.27K235.45K138.75K65.98K
Gross Profit128.09K164.52K84.22K-17.72K-245.45K62.40K
EBITDA-1.44M-1.04M-1.22M-811.47K-4.05M-4.11M
Net Income-1.55M-1.15M-1.64M-1.47M-5.15M-4.94M
Balance Sheet
Total Assets1.18M1.38M2.42M3.35M3.59M7.27M
Cash, Cash Equivalents and Short-Term Investments23.81K66.08K818.16K1.41M1.34M306.51K
Total Debt11.02K11.44K12.80K1.34M1.44M1.49M
Total Liabilities409.76K545.61K470.72K1.89M2.16M3.38M
Stockholders Equity766.98K834.81K1.95M1.47M1.43M3.89M
Cash Flow
Free Cash Flow-1.31M-796.85K-1.35M-1.47M-1.73M-3.00M
Operating Cash Flow-1.31M-796.85K-1.33M-1.47M-1.68M-2.39M
Investing Cash Flow-3.76K9.00K382.92K101.94K-48.77K-611.04K
Financing Cash Flow1.05M-1.95K539.10K1.35M2.77M783.92K

Blueberries Medical Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.02
Price Trends
50DMA
0.02
Positive
100DMA
0.02
Positive
200DMA
0.02
Positive
Market Momentum
MACD
<0.01
Negative
RSI
60.80
Neutral
STOCH
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BBM, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 60.80 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BBM.

Blueberries Medical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
49
Neutral
C$9.90M-9.82-167.41%55.74%-27.59%
46
Neutral
C$17.62M-1.56-461.32%-46.59%8.26%
43
Neutral
C$3.84M-6.3750.26%1.60%-213.10%
40
Underperform
C$1.95M-1.54-271.33%15.95%-1.81%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:BBM
Blueberries Medical
0.02
<0.01
33.33%
TSE:AYUR
Ayurcann Holdings Corp.
0.01
-0.02
-60.00%
TSE:MVMD
Mountain Valley MD
0.05
0.02
66.67%
TSE:BAMM
Body & Mind
0.03
0.00
0.00%
TSE:CDVA
CordovaCann
0.04
-0.08
-69.57%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 28, 2026